- Palsonify Commercial Launch Progress Over 200 enrollment forms received in Q4 2025, with more than 125 unique prescribers adopting the treatment.
- 2025 Financial Performance Q4 2025 net revenue reached $6.2M, including $5.4M in Palsonify product revenue and $800K from a licensing agreement.
- Cash Position and Runway Ended 2025 with $1.4B in cash after a January 2026 public offering, funding operations until 2030 despite $326.2M in annual cash burn.
- Phase 2/3 Trial Initiation Plans to launch the global Equilibrium ADCS study for atumelanant in Cushing’s disease by mid-2026 following promising Phase 2 results.
Pipeline Progress
The company's pipeline includes several late-stage candidates, including paltusotine for carcinoid syndrome and congenital adrenal hyperplasia (CAH), and atumelanant for CAH and Cushing's disease. Atumelanant has shown promising results in Phase 2 studies for Cushing's disease, with rapid and sustained reductions in cortisol levels. The company will initiate an operationally seamless global Phase 2/3 study, Equilibrium ADCS, in the first half of 2026. As per the management, they expect to communicate Phase 2 results for the BRAVEST trial at a scientific conference, aiming to motivate investigators and patients to participate in Phase 3.
Palsonify Launch Update
Regarding the launch of Palsonify, the company reported 200 enrollment forms in Q4 and is pleased with the uptake. Payer dynamics for Palsonify are progressing well, with most coverage already in place and prior authorizations proceeding smoothly. The company expects the cadence of the launch to be lumpy but is working to become the number one acromegaly treatment.
Valuation Metrics
The company's P/S Ratio stands at 777.35, indicating a high revenue multiple. The EV/EBITDA ratio is -8.29, reflecting the company's current loss-making status. With the expected revenue growth at 184.8% next year, the current valuation may be justified if the company continues to execute on its commercialization and clinical trials. The ROE and ROIC are -41.46% and -49.33%, respectively, highlighting the company's current investment phase.
Future Outlook
The company expects GAAP operating expenses to be around $606 million and non-GAAP operating expenses between $480 million and $520 million. The increased operating expenses are due to ongoing investments in clinical trials and commercialization activities for Palsonify. Crinetics Pharmaceuticals believes its existing cash and investments will fund operations until 2030, providing a significant runway to execute on commercialization and clinical trials.